FeesSafety
Pluang+

Pfizer set to pay its 352nd consecutive dividend on Dec 7, 2026, despite potential challenges ahead.

Company Fundamentals
19 Nov 2026, 16:44 WIB
Keith Speights
View Source
Neutral
Pfizer set to pay its 352nd consecutive dividend on Dec 7, 2026, despite potential challenges ahead.

Pfizer will pay its 352nd consecutive quarterly dividend on December 7, 2026, maintaining a strong track record for investors. The company faces challenges like a patent cliff, costly acquisitions, and clinical setbacks that could threaten this streak, but all three would likely need to occur to stop the dividend. Pfizer's substantial cash reserves and promising new drugs position it well to continue funding dividends at current levels. Investors seeking steady income may still find Pfizer an attractive option despite these risks.

Pfizer's dividend yield stands at a notable 6.04% as of Nov 19, 2026, 17:01 WIB, highlighting its appeal for income-focused investors. The stock trades at USD 27.97 with a market cap of $162.27 billion on Pluang, where the typical holding period is 158 days. Despite a slight 0.32% dip in price that day, Pfizer remains a significant player in the health sector with active trading volume of over 35 million shares.

More News (PFE)

Pfizer set to pay its 352nd consecutive dividend on Dec 7, 2026, despite patent cliff risks.

Pfizer set to pay its 352nd consecutive dividend on Dec 7, 2026, despite patent cliff risks.

Pfizer will pay its 352nd consecutive quarterly dividend on December 7, 2026, maintaining a long-standing payout streak. Although the company faces challenges like a patent cliff, costly acquisitions, and clinical trial setbacks, it currently has eno...

Company Fundamentals
Neutral
5 hours ago
Pfizer's strong Q3 and raised 2026 EPS guidance ease patent expiration fears, keeping it a Buy for investors.

Pfizer's strong Q3 and raised 2026 EPS guidance ease patent expiration fears, keeping it a Buy for investors.

Pfizer Inc. delivered strong Q3 results driven by its oncology portfolio, Eliquis, and tafamidis franchise, with Eliquis revenue growing 25.2% year-over-year to about $2.5 billion. Despite concerns about an upcoming patent expiration cycle lasting ar...

Company Fundamentals
Bullish
1 day ago
Pfizer beats Q3 revenue estimates, raises 2026 guidance, and shows strong margin growth.

Pfizer beats Q3 revenue estimates, raises 2026 guidance, and shows strong margin growth.

Pfizer reported Q3 revenue of $16.58 billion, exceeding estimates by $700 million, driven by a 32% growth in launched and acquired products and an improved gross margin of about 77%. The company raised its full-year 2026 revenue guidance to $62 billi...

Analyst Insights
Bullish
1 day ago
Three overlooked dividend stocks now yield over 5%, offering strong income potential with varied risk profiles.

Three overlooked dividend stocks now yield over 5%, offering strong income potential with varied risk profiles.

Three dividend stocks in healthcare, telecom, and financials—Pfizer, Verizon, and OneMain Holdings—currently yield over 5%, attracting income investors seeking high payouts. Pfizer offers a 5.94% yield with growing drug franchises but has tight free ...

Market News
Neutral
1 day ago
Conagra cuts dividend by 50% amid cash flow struggles, signaling market warning on sustainability.

Conagra cuts dividend by 50% amid cash flow struggles, signaling market warning on sustainability.

Conagra Brands cut its quarterly dividend from $0.35 to $0.175 due to negative free cash flow and high leverage, reflecting financial stress. The stock has declined over 38% in five years, showing market skepticism about dividend sustainability witho...

Market News
Bearish
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App